All In Biotech

Free tool

FAERS Monitor: Rezlidhia

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 215814 or its brand name (Rezlidhia, Olutasidenib). Reports on generic versions are filed under their own applications.

Reports

289

Serious

164

57% of reports

Hospitalization

114

Death reported

45

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use75
  • hospitalisation43
  • death40
  • fatigue27
  • nausea27
  • product dose omission issue25
  • product prescribing issue23
  • constipation17
  • transfusion13
  • pneumonia11
  • drug ineffective10
  • dyspnoea10
  • disease progression9
  • vomiting9
  • abdominal discomfort8

Reports by year received

View as table
YearReports
202341
202491
2025111
202646

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,870 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
transfusionSignal1390.453.11,061
product prescribing issueSignal2376.952.01,648
hospitalisationSignal4320.415.5778
off label useSignal756.25.1338
product dose omission issueSignal256.24.3105
constipationSignal175.73.661
disease progressionSignal95.52.929
abdominal discomfortSignal83.51.812
deathSignal403.42.567
fatigueSignal272.51.824
nauseaSignal272.51.723
pneumoniaSignal112.51.48
vomiting91.40.71
dyspnoea101.30.70
drug ineffective100.60.33

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.